Hypertension
Conditions
Interventions
Experimental group:Wear the bracelet 24 hours, and receive additional reminders and education of the results of the bracelet monitoring, including: ECG ECG monitoring, AI-ECG ECG analysis, sleep monit
Control group:Receive routine outpatient health education and receive guidance-recommended antihypertensive treatment.
Sponsors
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.18 years old =130/80mmHg, daytime blood pressure >=135/85mmHg, night blood pressure >=120/70mmHg), but their blood pressure <180/110mmHg. 4.had received lifestyle intervention, but did not receive hypertension medication. 5. Can use smart phones without barriers. 6.Have basic Chinese reading and writing ability and simple calculation ability. 7. Volunteer to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Secondary hypertension (including but not limited to the following conditions: renal parenchymatous hypertension, renal vascular hypertension, aorta Stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, polycystic nephropathy and drug-induced hypertension, etc.);Malignant hypertension, hypertensive emergency, hypertensive crisis and hypertensive encephalopathy. 2. Severe cardiopulmonary insufficiency [including but not limited to: Acute coronary syndrome, myocardial infarction, stroke, NYHA grade IV heart failure, large aneurysm or dissecting aneurysm, active myocarditis, complicated with severe valvular heart disease, grade II and above atrioventricular block, sick sinus syndrome, bradycardia (heart rate < 50) within 6 months (per minute) or other arrhythmias requiring antiarrhythmic medication, severe asthma or chronic obstructive pulmonary disease, severe sleep apnea, epilepsy, fainting, and other cardiorespiratory conditions that the investigators determined were not eligible for study participation.] 3.Diseases of the rheumatic system (currently using corticosteroids or anti-rheumatic drugs). 4.Diseases of the blood system (including but not limited to: anemia of unknown cause, lymphoma, leukemia, multiple myeloma, etc.). 5.Patients with active malignant tumors or a history of malignant tumors within 5 years prior to screening. 6. Chronic kidney disease stage 5 and patients undergoing hemodialysis or strict salt restriction therapy. 7.Gastrointestinal diseases or gastrointestinal surgery may affect drug absorption or excretion, such as gastrointestinal resection, active gastrointestinal inflammation, ulcers or gastrointestinal bleeding. 8.Vulnerable groups, including those with mental illness, those with cognitive impairment, critically ill patients, pregnant women, breastfeeding women, illiterates, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean arterial pressure change over 3 months;Blood pressure of patients monitored by 24-hour ambulatory Blood pressure (ABPM); | — |
Secondary
| Measure | Time frame |
|---|---|
| Home self-measured blood pressure the earliest time to reach the target;The number of antihypertensive drugs when the blood pressure reaches the target;Mean systolic/diastolic blood pressure change;Resting heart rate change; | — |
Countries
China
Contacts
Public ContactZhang Wenbin
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed